The IRIS III study: Pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight [2]

Diabetes, Obesity and Metabolism

Volumn 9, Issue 1, 2007, Pages 132-133

  Schöndorf, Thomass ^a,d   Forst, T ^a   Hohberg, C ^a   Pahler, S ^a   Link, C ^a,c   Roth, W ^a   Pfutzner A ^a,c   Lubben G ^b  

^a Institute for Clinical Research and Development   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c University of Applied Science   (Germany)

^d IKFE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 33845535490     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00582.x     Document Type: Letter

References (7)

1. Vitarius JA. The metabolic syndrome and cardiovascular disease. Mt Sinai J Med 2005; 72: 257-262.
2. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: A review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6: 850-863.
3. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism 2005; 54: 24-32.
4. Belcher G, Lambert C, Edwards G, Urquart R, Matthews DR. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005; 70: 53-62.
5. Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Pract 2005; 59: 134-142.
6. Pfützner A, Hohberg C, Lübben G et al. Pioneer Study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005; 37: 510-515.
7. Pfützner A, Schöndorf T, Seidel D et al. Impact of rosiglitazone on β-cell function, insulin resistance and cardiovascular risk markers - results from a double blind oral combination study with glimepiride. Metabolism 2006; 55: 20-25.